The PurpleLab^® Resource Center

Semaglutide has gone viral. Ozempic and other glucagon-like peptide-1 (GLP-1) receptor agonists are so popular that more than 24 million Americans—about 7% of the population—could be taking them for weight loss by 2035, according to the latest estimates. The medications have been hailed as “a significant leap forward in tackling obesity,” which affects 41.9% of…

This blog is part two in a series exploring the use of real-world evidence to produce meaningful insights in clinical pharma.  Pharmaceutical manufacturers do more than just produce medications that line pharmacy and hospital shelves: they also need to closely observe and respond to market conditions, changing clinical guidelines, and safety regulations, to ensure that…

This blog is part one in a series exploring the use of real-world evidence to produce meaningful insights in clinical pharma.  Clinical trials are crucial for developing new medications and treatments, but they require meticulous pre-planning and feasibility assessments, which can be extremely time-consuming. Real-world evidence (RWE) offers a promising solution to expedite this process….